Get these analyses to your inbox — https://axialfc.substack.com/ This is a newsletter for new financing events with some simple analysis. More well thought out work can be found at — https://axial.substack.com/ I figured that there is a diversity across desire for frequency of emails.
Axial invests and partners in early-stage life sciences companies. If you or someone you know has a great idea or company in life sciences, Axial would be excited to get to know you and possibly invest in your vision and company — info@axialsprawl.com
Life Sciences Financings and Commentary #3 — April 11, 2020 — April 17, 2020
Financings
Number of deals: 19 & Total capital invested: $705M
- 54gene raised $15M led by Adjuvant Capital. The company is building a business model similar to 23andMe — https://axial.substack.com/p/axial-23andme with a focus on Africa — https://techcrunch.com/2020/04/14/african-genomics-startup-54gene-raises-15m-led-by-adjuvant-capital/
- Alnylam Pharmaceuticals is a public company but their recent financing from Blackstone is noteworthy. Blackstone invested $100M in equity capital with $1B for half the royalties on inclisiran, up to $750M in loans, and $150M for an R&D pact that’s still being negotiated. This financing is another signal that more sophisticated capital markets (i.e. layered debt) is coming to life sciences.
